Table 2.

Patient Disposition and Discontinuation Reasons

Variable	Patients by Imatinib Dose
	400 mg (n = 157)		800 mg (n = 319)
	No.	%	No.	%
Treatment disposition
Continued initial treatment	132	84.1	256	80.3
Discontinued initial treatment	25	15.9	63	19.7
Reason for discontinuation
Adverse events	6	3.8	30	9.4
Abnormal laboratory value(s)	1	0.6	2	0.6
Unsatisfactory therapeutic effect	10	6.4	20	6.3
Patient withdrew consent	2	1.3	4	1.3
Protocol violation	3	1.9	1	0.3
Administrative problems	2	1.3	2	0.6
No longer required study drug	1	0.6	1	0.3
Lost to follow-up	0		2	0.6
Death	0		1	0.3
Most frequent adverse events leading to discontinuation*
Rash	1	0.6	5	1.6
Neutropenia	1	0.6	4	1.3
Nausea	1	0.6	3	0.9
Dyspnea	0		3	0.9
Thrombocytopenia	2	1.3	1	0.3

NOTE. Disposition in the intent-to-treat population as of December 31, 2007 (ie, data cutoff).

^*Safety population.